- Home
- OLP vs MLYS Comparison
OLP vs MLYS Comparison
Compare OLP & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLP
- MLYS
- Stock Information
- Founded
- OLP 1982
- MLYS 2019
- Country
- OLP United States
- MLYS United States
- Employees
- OLP N/A
- MLYS N/A
- Industry
- OLP Real Estate Investment Trusts
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- OLP Real Estate
- MLYS Health Care
- Exchange
- OLP Nasdaq
- MLYS Nasdaq
- Market Cap
- OLP 569.9M
- MLYS 1.0B
- IPO Year
- OLP N/A
- MLYS 2023
- Fundamental
- Price
- OLP $24.27
- MLYS $15.02
- Analyst Decision
- OLP Strong Buy
- MLYS Strong Buy
- Analyst Count
- OLP 1
- MLYS 4
- Target Price
- OLP $28.00
- MLYS $27.00
- AVG Volume (30 Days)
- OLP 78.9K
- MLYS 892.7K
- Earning Date
- OLP 08-05-2025
- MLYS 08-12-2025
- Dividend Yield
- OLP 7.46%
- MLYS N/A
- EPS Growth
- OLP N/A
- MLYS N/A
- EPS
- OLP 1.35
- MLYS N/A
- Revenue
- OLP $92,152,000.00
- MLYS N/A
- Revenue This Year
- OLP $11.87
- MLYS N/A
- Revenue Next Year
- OLP $4.72
- MLYS N/A
- P/E Ratio
- OLP $17.91
- MLYS N/A
- Revenue Growth
- OLP 3.31
- MLYS N/A
- 52 Week Low
- OLP $22.32
- MLYS $8.24
- 52 Week High
- OLP $30.45
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- OLP 48.30
- MLYS 55.98
- Support Level
- OLP $23.79
- MLYS $13.44
- Resistance Level
- OLP $24.32
- MLYS $14.70
- Average True Range (ATR)
- OLP 0.49
- MLYS 0.70
- MACD
- OLP -0.02
- MLYS 0.14
- Stochastic Oscillator
- OLP 36.86
- MLYS 92.31
About OLP One Liberty Properties Inc.
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.